Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in Recurrent High-Grade Glioma
NCT04588987Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in glioma, glioblastoma (GBM), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT04588987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588987.